NCT01802684已完成2 期
OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study.
GERCOR - Multidisciplinary Oncology Cooperative Group16 个研究点 分布在 1 个国家目标入组 49 人开始时间: 2013年5月1日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 49
- 试验地点
- 16
- 主要终点
- Progression free survival at 6 months
研究概览
简要总结
Evaluation of feasibility of adding aflibercept to an oxaliplatin-based regimen rather than a continuous administration of chemotherapy until progression, in order to decrease the risk of severe toxicities.
详细描述
The addition of aflibercept to the standard FOLFIRI regimen as second-line therapy was evaluated in a large phase III study (EFC10262-VELOUR). This new combination significantly improved both PFS (4.7 to 6.9 months, HR=0.76; P=.00007) and OS (12.1 to 13.5 months, HR=0.82; P=.0032). In the evaluable population (86.5%), the tumor response rate was also improved when adding aflibercept (ORR=19.8% [16.4-23.2]) to the FOLFIRI regimen (ORR=11.1% [8.5-13.8]).
This trial will evaluate the feasibility of adding aflibercept to an oxaliplatin-based regimen as a first-line therapy , using the OPTIMOX strategy rather than a continuous administration of chemotherapy until progression, in order to decrease the risk of severe toxicities.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated informed consent, and willing and able to comply with protocol requirements,
- •Histologically proven adenocarcinoma of the colon and/or rectum,
- •Metastatic disease confirmed,
- •No prior therapy for metastatic disease (in case of previous adjuvant therapy, interval from end of chemotherapy to relapse must be >6 months for fluoropyrimidine alone or >12 months for oxaliplatin-based, bevacizumab-based, cetuximab-based therapy,
- •Duly documented inoperable metastatic disease, ie not suitable for complete carcinological surgical resection,
- •At least one measurable or evaluable lesion as assessed by CT-scan or MRI (Magnetic Resonance Imaging) according to RECIST v1.1,
- •Age ≥18 years,
- •ECOG Performance status (PS) 0-2,
- •Hematological status: neutrophils (ANC) ≥1.5x109/L; platelets ≥100x109/L; haemoglobin ≥9g/dL,
- •Adequate renal function: serum creatinine level <150µM,
- •Adequate liver function: serum bilirubin ≤3 x upper normal limit (ULN), alkaline phosphatase <5xULN,
- •Proteinuria <2+ (dipstick urinalysis) or ≤1g/24hour,
- •Baseline evaluations: clinical and blood evaluations performed no more than 2 weeks (14 days) prior to confirmation of eligibility, tumor assessment (chest X ray, CT-scan or MRI, evaluation of non-measurable lesions) no more than 3 weeks (21 days) prior to confirmation of eligibility,
- •For female patients of childbearing potential, negative serum or urine pregnancy test within 1 week (7 days) prior of starting study treatment,
- •Female patients of childbearing potential must commit to using reliable and effective methods of contraception during the trial and until at least six months after the end of study treatment. Females are neither pregnant nor in breastfeeding. Male patients with a partner of childbearing potential must agree to use effective contraception in addition to the contraceptive method used by their partner during the trial and until at least six months after the end of study treatment.
- •Registration in a national health care system (CMU included for France).
排除标准
- •History or evidence upon physical examination of CNS metastasis unless adequately treated (e.g. non irradiated CNS metastasis, seizure not controlled with standard medical therapy),
- •Exclusive bone metastasis,
- •Uncontrolled hypercalcemia,
- •Pre-existing permanent neuropathy (NCI grade ≥2),
- •Uncontrolled hypertension (defined as systolic blood pressure >150 mmHg and/or diastolic blood pressure >100 mmHg despite optimal medical therapy), or history of hypertensive crisis, or hypertensive encephalopathy,
- •Concomitant unplanned antitumor therapy (e.g. chemotherapy, molecular targeted therapy, immunotherapy/ radio-immunotherapy),
- •Treatment with any other investigational medicinal product within 28 days prior to study entry,
- •Other serious and uncontrolled non-malignant disease,
- •Other concomitant or previous malignancy, except: i/ adequately treated in-situ carcinoma of the uterine cervix, ii/ basal or squamous cell carcinoma of the skin, iii/ cancer in complete remission for >5 years,
- •Any other serious and uncontrolled non-malignant disease, major surgery or traumatic injury within the last 28 days
- •Patients with known allergy to any excipient to study drugs,
- •History of myocardial infarction and/or stroke within 6 months prior to study entry,
- •Bowel obstruction.
结局指标
主要结局
Progression free survival at 6 months
时间窗: time interval from inclusion to the date of first documented disease progression or death from any cause, whichever occurs first. Assessed at 6 months.
次要结局
- Median Progression Free Survival(time interval from inclusion to the date of first documented disease progression or death from any cause, whichever occurs first. Assessed up to 3 years after the beginning of the study)
- duration of disease control (DDC)(sum of PFS of each active treatment course. Assessed up to 3 years after the beginning of the study)
- tumor Response Rate (RR)(Assessed every 2 months during treatment period (- Estimated treatment duration per patient : 16 months).)
- Curative salvage surgery(assessed up to 3 years after the beginning of the study)
- Health related Quality of life(Assessed from study entry to 1 month after last study drug administration and up to 3 years after the beginning of the study.)
- Overall Survival(time interval from inclusion to the date of death from any cause. Assessed up to 3 years after the beginning of the study.)
- Safety(Assessed from study entry to 1 month after last study drug administration, assessed up to 3 years after the beginning of the study)
研究者
研究点 (16)
Loading locations...
相似试验
进行中（未招募）
不适用
First-line Combination of Capecitabine and Oxaliplatin Plus Bevacizumab in Elderly Patients With Metastatic Colorectal CancerElderly Metastatic Colorectal Cancer PatientsNCT03451370Istituto Oncologico Veneto IRCCS121
Unknown
1 期
Phase I Study of the Combination of Apatinib and POFGastric AdenocarcinomaNCT03244774Fujian Cancer Hospital18
Unknown
2 期
Study of the Combination of Apatinib and POFGastric AdenocarcinomaNCT03707639Fujian Cancer Hospital26
已完成
2 期
Phase II Study of Oxaliplatin in Combination With 5-Fu in 1st Line Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Head and NeckHead and Neck CancerNCT00611754Sanofi15
终止
1 期
Study of Aflibercept as Maintenance Therapy Following Induction With Aflibercept in Combination With XELOX, as First-Line Treatment for Metastatic Colorectal Cancer PatientColorectal Cancer MetastaticNCT01955629Sanofi4